In 2016, Watrowski et al. illustrated that the combination of platelet counts (>350 × 109 U/L) with CA125 levels (>35 U/mL) was able to distinguish ovarian cancer patients from benign controls with an 81% sensitivity at 94% specificity, implying that platelet count may be a suitable diagnostic method for identifying ovarian cancer, specifically in settings where limited health care options are available [122]. The gene discussed is MUC16; the disease is ovarian cancer.